Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2007 | 1 |
2009 | 1 |
2010 | 1 |
2019 | 2 |
2023 | 1 |
2024 | 1 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.
Lancet. 2019.
PMID: 31679945
Clinical Trial.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators.
Mok TSK, et al.
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
Lancet. 2019.
PMID: 30955977
Clinical Trial.
Item in Clipboard
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group.
Qin S, et al.
Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24.
Lancet. 2023.
PMID: 37499670
Clinical Trial.
Item in Clipboard
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators.
Sangro B, et al.
Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19.
Ann Oncol. 2024.
PMID: 38382875
Free article.
Clinical Trial.
Item in Clipboard
Morphology of pararectal lymph nodes in rectal cancer after neoadjuvant therapy.
Kolotova NM, Maiborodin IV, Fursov SA, Lushnikova EL, Zarubenkov OA, Maiborodina VI.
Kolotova NM, et al. Among authors: zarubenkov oa.
Bull Exp Biol Med. 2010 Aug;149(2):250-4. doi: 10.1007/s10517-010-0919-y.
Bull Exp Biol Med. 2010.
PMID: 21113503
English, Russian.
Item in Clipboard
[The structure of the rat lymph nodes draining purulent inflammation region after interleukin-2 treatment].
Maĭborodin IV, Strel'tsova EA, Egorov DV, Zarubenkov OA, Shevela AI, Sidorov SV, Rodisheva TM.
Maĭborodin IV, et al. Among authors: zarubenkov oa.
Morfologiia. 2009;135(3):50-4.
Morfologiia. 2009.
PMID: 19860330
Russian.
Item in Clipboard
[Changes in the aggregated lymphoid nodules and in the mesenterial lymph nodes of rats after the administration of a chemotherapeutic drug complex: response similarities and differences].
Maĭborodin IV, Strunkin DN, Maĭborodina VI, Kulikova OV, Lebedev AA, Zarubenkov OA, Cherenkova MM.
Maĭborodin IV, et al. Among authors: zarubenkov oa.
Morfologiia. 2007;132(5):68-73.
Morfologiia. 2007.
PMID: 18198676
Russian.
Item in Clipboard
Cite
Cite